Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer has propelled the development of HER-targeting monoclonal antibodies (mAb) such as trastuzumab and pertuzumab, which led to dramatic improvements in survival outcomes. Lately, the great strides made toward d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rassy, Elie, Rached, Layal, Pistilli, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article(s) from the Special Issue on: Antibody-drug Conjugates; Edited by Giuseppe Curigliano, Hope Rugo
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636477/
https://www.ncbi.nlm.nih.gov/pubmed/36334569
http://dx.doi.org/10.1016/j.breast.2022.10.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636477/
https://www.ncbi.nlm.nih.gov/pubmed/36334569
http://dx.doi.org/10.1016/j.breast.2022.10.016

Ejemplares similares